The global First-in-Human (FIH) Services market size is predicted to grow from US$ 667 million in 2025 to US$ 1299 million in 2031; it is expected to grow at a CAGR of 11.7% from 2025 to 2031.

First-in-Human Services refer to specialized services that support the planning, execution, and management of First-in-Human (FIH) clinical trials. These services are critical for the successful transition of a drug or therapeutic product from preclinical development to initial testing in human subjects. FIH trials are typically the first time a new drug is administered to humans, making the associated services essential for ensuring safety, compliance, and scientific validity.First-in-Human Services are essential for minimizing risks associated with the early testing of new drugs in humans, ensuring regulatory compliance, and generating reliable data that can influence subsequent phases of drug development. These services help streamline the clinical trial process, improve efficiency, and enhance the likelihood of successful product development.

United States market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key First-in-Human (FIH) Services players cover WuXi AppTec, Allucent, Altasciences, LAXAI, Lonza, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information) newest research report, the ?First-in-Human (FIH) Services Industry Forecast? looks at past sales and reviews total world First-in-Human (FIH) Services sales in 2024, providing a comprehensive analysis by region and market sector of projected First-in-Human (FIH) Services sales for 2025 through 2031. With First-in-Human (FIH) Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world First-in-Human (FIH) Services industry.

This Insight Report provides a comprehensive analysis of the global First-in-Human (FIH) Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on First-in-Human (FIH) Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global First-in-Human (FIH) Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for First-in-Human (FIH) Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global First-in-Human (FIH) Services.

This report presents a comprehensive overview, market shares, and growth opportunities of First-in-Human (FIH) Services market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Drugs
    Medical Device

Segmentation by Application:

    Pharmaceutical Companies
    Contract Research Organizations (CROs)
    Academic Institutions and Research Centers
    Medical Device Companies

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    WuXi AppTec
    Allucent
    Altasciences
    LAXAI
    Lonza
    Syneos Health
    CD BioSciences
    Fortrea
    Certara
    Evotec
    Aixial Group
    Quotient Sciences
    Sofpromed
    Spaulding Clinical
    Biotrial
    Crystal Pharmatech Co., Ltd
    Avania